|
Collaborative Post | Scotland has a weight problem that is well-documented, longstanding, and worsening. According to the Scottish Health Survey 2024, published by the Scottish Government in October 2025, 31% of Scottish adults are living with obesity and 66% are living with overweight including obesity. That is two-thirds of the adult population. The scale of the problem is not news. What is changing is the response: a new policy framework, a significant shift in how NHS Scotland is approaching weight management medication, and a growing private treatment sector filling the gap where NHS access has not yet reached. This article sets out the data, what is being done at a policy level, and what treatment options currently exist for Scottish adults.  Scotland's obesity rates are among the highest in the UK, with significant variation by area deprivation. The most deprived communities carry a disproportionate burden that is reflected in both the data and the policy response. The Scottish data: what the numbers showThe most comprehensive source is the Scottish Health Survey, an annual population survey conducted by the Scottish Government. The 2024 edition, drawing on data collected across the year, presents the following picture:  Scottish obesity data 2024: 31% of adults live with obesity, 66% with overweight including obesity, 36% obesity rate in the most deprived areas, and 18% of children at risk of obesity -- the highest level ever recorded in the survey time series. Source: Scottish Health Survey 2024, gov.scot.
The trajectory is clear. The Obesity Action Scotland briefing from March 2025 notes that Scotland currently has an estimated 1.5 million adults living with obesity, within a total of approximately 3.4 million with overweight including obesity. A 2025 modelling study published on medRxiv projected that, without significant intervention, these figures will increase substantially by 2040, with the burden falling disproportionately on older age groups and the most deprived communities. Scottish obesity prevalence has risen from 24% in 2003 to 31% in 2024. In the most deprived quintile, the obesity rate is 36% -- 50% higher than in the least deprived quintile (24%). In 2024, 18% of children were at risk of obesity, the highest level in the time series. Scottish Health Survey 2024. gov.scot/publications/scottish-health-survey-2024. Published October 2025. Why Scotland's rates are higher than the UK averageScotland consistently records higher obesity rates than England. The Obesity Action Scotland report identifies several structural factors that explain the divergence:
The Scottish Government's policy responseA Healthier Future: Scotland's Diet and Healthy Weight Delivery Plan The primary policy framework is A Healthier Future, published in 2018 and updated subsequently. The plan sets out a vision that everyone in Scotland has a healthy weight, with four priority outcomes: children have the best start in life; people have access to effective weight management services; leaders across all sectors promote healthy weight; and diet-related health inequalities are reduced. The plan includes a target to halve the prevalence of child obesity by 2030. Given current trends, that target is unlikely to be met, and the Scottish Government has faced criticism from health organisations including Obesity Action Scotland for the pace of progress on food environment regulation. NHS board weight management funding The Scottish Government provides funding to all 14 NHS health boards to deliver adult and children's weight management services, in line with Public Health Scotland national standards and the 2018 Type 2 Diabetes Prevention Framework. From financial year 2025/26, this funding has been permanently baselined, meaning it is no longer subject to annual funding decisions. The baseline funding guarantees that weight management services exist across all NHS boards, though the capacity and waiting times within those services vary considerably by board. Good Food Nation Act 2022 Scotland passed the Good Food Nation (Scotland) Act 2022, which requires the Scottish Government and relevant public bodies to produce Good Food Nation Plans. The national plan was adopted in 2024. The act provides a legislative basis for a more systemic approach to food environment improvements, including actions on availability, labelling, and promotion of healthy food. Local plans from councils and health boards are expected to follow.  Scotland's approach to obesity combines population-level food environment policy, targeted weight management services, and the phased introduction of GLP-1 medications through NHS Scotland. The 2024 consensus statement coordinates the clinical approach across all 14 health boards. How NHS Scotland is approaching GLP-1 weight management medication The SMC approval and what it means In November 2024, the Scottish Medicines Consortium (SMC) approved tirzepatide (Mounjaro) for weight management in adults with a BMI of 30 kg/m2 or above and at least one weight-related comorbidity. This is a significantly broader access threshold than NICE's guidance for England and Wales, which set the minimum at BMI 35 kg/m2. Scotland approved the medication based on the same clinical evidence but with criteria more closely aligned with the MHRA-approved label. The SMC had previously approved semaglutide (Wegovy) in October 2023. Both medications are now approved for NHS Scotland use, giving Scotland a broader eligibility framework for GLP-1 weight management treatment than exists in England at equivalent NHS funding thresholds. The Once for Scotland consensus statement In October 2024, the Scottish Government published a "Once for Scotland" consensus statement on GLP-1 and GLP-1/GIP receptor agonist medications for obesity. The document was designed to produce consistent national criteria across all 14 NHS health boards, preventing the postcode variation in access that emerged in England. The statement sets out a phased implementation approach:
 NHS Scotland's phased GLP-1 rollout, from specialist services in March 2025 to GP prescribing from June 2025 onwards. Scotland's SMC criteria (BMI 30+) are broader than NICE's threshold in England (BMI 35+). Source: Scottish Government consensus statement, October 2024. The capacity gap The SMC approval and consensus statement create the framework. Delivering within it is a different challenge. NHS Lothian, for example, added tirzepatide to its formulary in February 2025 but as of early 2026 was still developing the clinical pathways needed to prescribe it, meaning eligible Edinburgh patients could not yet access treatment through the NHS pathway. This pattern is likely to be repeated across other boards as they build the specialist workforce and infrastructure required. There are approximately 1 million adults in Scotland with a BMI above 30, according to the consensus statement's own estimate. The capacity of NHS Scotland specialist weight management services to reach that population on any relevant timescale is genuinely limited. Private access is, for most eligible Scots, the only near-term route to treatment. NHS Scotland's own consensus statement estimates approximately 1 million adults in Scotland have a BMI above 30 kg/m2, the threshold for SMC-approved tirzepatide. NHS specialist weight management services do not currently have the capacity to reach this population. Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity. October 2024. Private treatment access in ScotlandFor the majority of Scottish adults who meet clinical criteria but cannot access NHS treatment through the current phased rollout, regulated private prescribing provides an alternative pathway. The GPhC introduced rules in February 2025 requiring online pharmacies to independently verify weight and BMI rather than relying on self-reported data, and their April 2026 review found standards failures across a significant proportion of pharmacies inspected, making provider selection important. The criteria for private prescribing align with the MHRA-approved label: BMI 30 or above with at least one weight-related health condition. For eligible patients in Scotland who cannot wait for NHS pathway development, supervised tirzepatide prescribing through Voy includes specialist prescribing, dose support, clinical monitoring, and home delivery throughout treatment. Frequently asked questionsCan I get Mounjaro on the NHS in Scotland?
Yes, if you meet the current phased eligibility criteria. NHS Scotland began initiating tirzepatide (Mounjaro) in specialist weight management services from March 2025 for adults with a BMI of 38 kg/m2 or above and at least one weight-related comorbidity. From June 2025, eligible patients began accessing treatment through GP practices, starting with those with the greatest clinical need. Waiting times and pathway availability vary by health board. NHS Lothian, for example, was still developing its prescribing pathway as of early 2026. If you believe you may be eligible, contact your GP. Is Scotland's NHS Mounjaro access broader than England's? Yes. The Scottish Medicines Consortium approved tirzepatide at a minimum BMI of 30 kg/m2 with one weight-related comorbidity. NICE in England approved it at BMI 35 kg/m2. The current phased rollout criteria in both countries are more restrictive than the full approved indication, but Scotland's ultimate eligibility framework is broader. The "Once for Scotland" approach is also designed to produce consistent access criteria across all 14 health boards, avoiding the postcode variation seen in England. What is the Scottish Government doing about obesity? The primary framework is A Healthier Future: Scotland's Diet and Healthy Weight Delivery Plan, published in 2018, which includes a target to halve child obesity by 2030. The Scottish Government funds weight management services in all 14 NHS health boards, with this funding permanently baselined from 2025/26. The Good Food Nation Act 2022 provides a legislative basis for food environment improvements. The October 2024 GLP-1 consensus statement coordinates the NHS rollout of weight management medication. Critics including Obesity Action Scotland have called for faster progress on food environment regulation, including restrictions on the promotion of high-fat, high-sugar products. Why does Scotland have higher obesity rates than England? Several structural factors contribute: higher rates of area deprivation concentrated in post-industrial communities; dietary patterns shaped by food environment and affordability; geographic barriers to specialist services in rural and remote areas; and a legacy of socioeconomic disadvantage in communities that were dependent on heavy industry. The association between deprivation and obesity is particularly pronounced in Scotland, with the most deprived quintile recording a 36% obesity rate compared to 24% in the least deprived quintile. Is private Mounjaro available in Scotland? Yes. CQC-regulated providers offering supervised tirzepatide treatment operate across Scotland via digital clinical consultation. Private prescribing requires a clinical assessment confirming BMI and eligibility, and ongoing monitoring. From February 2025, GPhC rules require online pharmacies to independently verify weight and BMI. For adults who meet clinical criteria and cannot access NHS treatment through current rollout pathways, regulated private treatment is available with the same licensed medications. Expect costs in the range of £150 to £250 per month depending on dose and provider. This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any weight loss treatment. Individual results may vary. Treatment is subject to clinical suitability assessment. Sources
Comments are closed.
|
Search my blog ...
This page contains collaborative articles written by guest contributors that do not reflect my personal experiences or opinions. All information is provided in good faith and for general interest only.
Categories ...Read my latest blog post!Subscribe below to receive regular updates by email:
Archives
June 2026
Guest Post Disclaimer
The articles on this page are guest posts and reflect the views of the author, not Fifty & Fab. While I occasionally feature guest content on my blog, I do not personally endorse or promote any specific services, products, or companies mentioned. Please conduct your own research and use discretion before making any financial, health, or lifestyle decisions. Please note: This content may relate to a niche that is considered sensitive (e.g. gambling, cryptocurrency, international finance or CBD). The inclusion of this post does not imply endorsement or recommendation, and I cannot be held responsible for any outcomes resulting from its content or links. GambleAware.Org |